• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MENTOR TEXAS ARTOURA BREAST TISSUE EXPANDER; EXPANDER, SKIN, INFLATABLE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MENTOR TEXAS ARTOURA BREAST TISSUE EXPANDER; EXPANDER, SKIN, INFLATABLE Back to Search Results
Catalog Number TEXP140RUH
Medical Device Problem Code Material Rupture (1546)
Health Effect - Clinical Code No Code Available (3191)
Date of Event 09/12/2018
Type of Reportable Event Serious Injury
Additional Manufacturer Narrative
Since the device has not been returned for analysis, no product failure analysis can be conducted, and no determination of possible contributing factors can be made.As such, the investigation will be closed.If the complaint device is received in the future, the investigation will be reopened and conducted as appropriate.The device history record (dhr) was reviewed, and no anomalies were found related to this complaint.In addition, the dhr review verifies that the device was manufactured in accordance with documented specification and procedures.(b)(4).
 
Event or Problem Description
It was reported that a (b)(6)-year-old female patient underwent a breast reconstruction revision procedure with a mentor artoura breast tissue expander 850cc device that deflated after implantation.During a visit to the doctor¿s office, it was discovered that the device in the patient¿s right breast had collapsed.As a result, the patient will undergo explantation on (b)(6) 2018.
 
Additional Manufacturer Narrative
On 11/19/2018, the mentor product analysis lab has received the device for evaluation on 11/28/2018, mentor completed the investigation on the suspect medical device.The device was received with no fluid.Yellow material was observed within the device.During a rent was observed on the anterior aspect, at junction of shell and patch.Microscopic examination of the edges of the rent gave no indications as to cause.No other anomalies were observed.The complaint was confirmed since a rupture was found on the device.Nonetheless, a microscopic examination of the edges of the rent was performed and it did not provide conclusive evidence of what could be the root cause.At this time is not possible to determine the origin of the yellow material observed.Mentor products are 100% visually inspected prior to release in addition to thorough in-process testing during several stages of the manufacturing process.Mentor product analysis lab concluded that the rent occurred sometime subsequent to the removal of the device from its protective packaging.(b)(4).
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ARTOURA BREAST TISSUE EXPANDER
Common Device Name
EXPANDER, SKIN, INFLATABLE
Manufacturer (Section D)
MENTOR TEXAS
3041 skyway circle north
irving TX 75038
MDR Report Key7993645
Report Number1645337-2018-06323
Device Sequence Number1487976
Product Code LCJ
UDI-Device Identifier00081317009573
UDI-Public00081317009573
Combination Product (Y/N)N
Initial Reporter StateIN
Initial Reporter CountryUS
Number of Events Summarized1
Summary Report (Y/N)N
Device Implanted Year2018
Device Explanted Year2018
Reporter Type Manufacturer
Report Source health professional
Initial Reporter Occupation Other
Type of Report Initial,Followup
Report Date (Section B) 10/02/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Expiration Date10/16/2019
Device Catalogue NumberTEXP140RUH
Device Lot Number6983391
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer11/19/2018
Initial Date Received by Manufacturer 10/02/2018
Supplement Date Received by Manufacturer11/19/2018
Initial Report FDA Received Date10/22/2018
Supplement Report FDA Received Date11/29/2018
Patient Sequence Number1
Outcome Attributed to Adverse Event Required Intervention;
Patient Age56 YR
-
-